Explain this page
Arphra AIPlain-English read on Jazz Pharmaceuticals plc’s valuation06-10today
- JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies3d
- Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration4d
- Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies4d
- Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia5d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $257.44 (+14.59%)
Candlestick · 1Y
Open in chart workstation →JAZZ
224.66+110.43%H 243.32L 105.00MA50 220.26MA200 175.05Avg vol 929K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.00% | -2.55% | -6.16% | +24.38% | +34.53% | +32.15% | +110.43% | +75.15% | +26.77% | +58.30% | +1167.12% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$224.50
135 sh
Bid
$218.00
2 sh
Ask
$233.08
44 sh
Spread
$15.080
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapieszacks.com·Jun 18, 2026
- Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaborationbenzinga.com·Jun 17, 2026
- Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodiesprnewswire.com·Jun 17, 2026
- Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomniaprnewswire.com·Jun 16, 2026
- Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomniaprnewswire.com·Jun 16, 2026
- JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Studyzacks.com·Jun 15, 2026
- Jazz Pharmaceuticals lung cancer drug fails main trial goalreuters.com·Jun 12, 2026
- Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancerprnewswire.com·Jun 12, 2026
Recent analyst activity
DB- Jun 10, 2026GradeBuy → BuyJazz Pharmaceuticals (JAZZ) PT Raised to $307 at BofA SecuritiesBank of America Securities
- Jun 09, 2026GradeMarket Perform → Market PerformBernstein SocGen Reiterates Market Perform Rating on Jazz Pharmaceuticals (JAZZ)Bernstein
- Jun 09, 2026PT$256.00Truist Securities Assumes Jazz Pharmaceuticals (JAZZ) at BuyTruist Financial
Peers
No peer list available for JAZZ.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|